Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 3/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26599109 | 0.81 | AKR1B1 (0.38) | ALDH1A1AKR1B1MEN1KMT2ATDP1 | |
| SCHEMBL29953022 | 0.79 | CES2 (0.39) | ALDH1A1AKR1B1HTTFFAR4MPO | |
| SCHEMBL1807270 | 0.79 | CES2 (0.39) | ALDH1A1AKR1B1HTTFFAR4MPO | |
| SCHEMBL6194272 | 0.79 | PNMT (0.56) | ALDH1A1AKR1B1MEN1KMT2ATDP1 | |
| SCHEMBL30801131 | 0.79 | IDO1 (0.50) | ALDH1A1MEN1KMT2ATDP1PNMT | |
| SCHEMBL168712 | 0.79 | IDO1 (0.50) | ALDH1A1MEN1KMT2ATDP1PNMT | |
| SCHEMBL1980395 | 0.78 | CES2 (0.38) | AKR1B1FFAR4MPOIDO1TAAR1 | |
| SCHEMBL15561430 | 0.77 | METTL3 (0.43) | ALDH1A1MEN1KMT2ATDP1MPO | |
| SCHEMBL5412834 | 0.77 | GABRA1 (0.44) | AKR1B1PNMTMPOP2RX7IDO1 | |
| SCHEMBL3278229 | 0.77 | AKR1B1 (0.43) | AKR1B1PNMTHTTFFAR4MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528773-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2026-01-20 | — | — | US | disclosed |
| EP-4511355-A2 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FundaMental Pharma GmbH (DE) | 2025-02-26 | — | — | EP | disclosed |
| US-20230348387-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2023-11-02 | — | — | US | disclosed |
| WO-2023203254-A2 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2023-10-26 | — | — | WO | disclosed |
| US-20230174486-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2023-06-08 | — | — | US | disclosed |
| CN-115867534-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-4146624-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | disclosed |
| EP-4146623-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | disclosed |
| CN-115803025-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2023-03-14 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-7795292-B2 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same | ALLERGAN, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7696238-B2 | Substituted benzo[d]isoxazol-3-yl amine compounds as analgesics | GRUENENTHAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-7696238-B2 | Substituted benzo[d]isoxazol-3-yl amine compounds as analgesics | GRUENENTHAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20080194650-A1 | ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS | ALLERGHAN, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | GRUENENTHAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | GRUENENTHAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| CN-101044120-A | Unsubstituted and substituted 4-benzyl-1, 3-dihydro-imidazole-2-thiones useful as specific or selective alpha 2 adrenergic agonists and methods of use thereof | ALLERGAN INC (US) | 2007-09-26 | — | — | CN | disclosed |
| EP-1797044-A2 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME | Allergan, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006036512-A2 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME | ALLERGAN, INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069142-A1 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same | ALLERGAN, INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348387-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | ALDH1A1 3200/4885AKR1B1 2826/4885MEN1 2340/4885 |
| US-12528773-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, GAA | ALDH1A1 1241/4885AKR1B1 2133/4885MEN1 3839/4885 |
| US-20060069142-A1 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same | ADRB2, ADRB1, ADRA2C | ALDH1A1 417/4885AKR1B1 507/4885MEN1 3529/4885 |
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | KCNQ1, KCNQ2, KCNQ3 | ALDH1A1 1965/4885AKR1B1 1918/4885MEN1 3801/4885 |
| US-20230174486-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | ALDH1A1 3200/4885AKR1B1 2826/4885MEN1 2340/4885 |
| US-20080194650-A1 | ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS | ADRB2, ADRA2C, ADRA2A | ALDH1A1 389/4885AKR1B1 336/4885MEN1 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.